Telix Pharmaceuticals

Telix Pharmaceuticals Debt

The Debt of Telix Pharmaceuticals (TLX.AX) as of Nov 19, 2026 is 467.11 M USD. In the previous year, Debt was 360.16 M USD — a change of 29.69% (higher).

Debt

467.11 MUSD

YoY

29.69%

Last updated:

In 2025, Telix Pharmaceuticals's total debt was 467.11 M USD, a 29.69% change from the 360.16 M USD total debt recorded in the previous year.

The Telix Pharmaceuticals Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
1.73 M USD
Jan 1, 2019
2.13 M USD
Jan 1, 2020
2.21 M USD
Jan 1, 2021
2.54 M USD
Jan 1, 2022
6.77 M USD
Jan 1, 2023
12.26 M USD
Jan 1, 2024
360.16 M USD
Jan 1, 2025
467.11 M USD
The Telix Pharmaceuticals Debt history
YEARDebtYoY
467.11 MUSD+29.69%
360.16 MUSD+2,836.74%
12.26 MUSD+81.04%
6.77 MUSD+166.81%
2.54 MUSD+15.04%
2.21 MUSD+3.57%
2.13 MUSD+23.24%
1.73 MUSD+400.64%
345,400.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Debt Details

Understanding Telix Pharmaceuticals's Debt Structure

Telix Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Telix Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Telix Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Telix Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Telix Pharmaceuticals stock

Debt of Telix Pharmaceuticals is 467.11 M USD in 2025.

Debt of Telix Pharmaceuticals changed from 360.16 M USD to 467.11 M USD, representing a 29.69% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Telix Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals